Health Care Utilization & Costs For Cystic Fibrosis Patients with Pulmonary Infections

Amy K. O’Sullivan, PhD
i3 Innovus
Jane Sullivan, MPH
i3 Innovus
Keiko Higuchi, MPH
Gilead Sciences Inc.
A. Bruce Montgomery, MD
Gilead Sciences Inc.


Purpose: To examine patterns of health care utilization and costs among cystic fibrosis (CF) patients with pulmonary infections.

Design: Retrospective administrative claims database analysis.

Methodology: We used administrative claims data (including both medical and pharmacy claims) to examine health care utilization and costs among CF patients with pulmonary infections over one year. We conducted a subgroup analysis in which we examined selected outcome measures among patients with tobramycin for inhalation (TIS) prescriptions by the number of TIS prescriptions filled.

Principal findings: Among 1,064 CF patients identified with pulmonary infections, 80% had at least one CF-related office visit, 34% had a CF-related hospital stay, and 95% filled at least one prescription over one year. Total annual CF-related health care costs averaged $29,000 plus $20,000 for prescription drugs. In the subgroup analysis, there was a trend towards longer lengths of stay and higher inpatient costs with fewer numbers of TIS prescriptions filled.

Conclusion: CF patients with pulmonary infections have substantial levels of health care utilization and costs.

Our most popular topics on